Biomaterial Database

Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. 2008

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Department of Paediatric Nephrology, Babol Medical University, Babol, Islamic Republic of Iran. hadisorkhi@yahoo.com

The aim of this study was to determine the efficacy of hepatitis B virus (HBV) vaccination and the response to vaccine in individuals on haemodialysis with and without HCV infection. From April 2000 to September 2003 all haemodialysis patients referred to the haemodialysis department in a Babol hospital received 4 microg vaccine intramuscularly at 0, 1, and 6 months. All were negative for HBV infection markers (HBcAb, HBsAg and HBsAb). Of 62 patients, 53 (85.5%) responded to vaccination and 26 (49.1%) were high responders. All individuals with HCV infection responded to vaccination. Duration of haemodialysis had no effect on response to vaccination.

UI	MeSH Term	Description	Entries
D007115	Immunization Schedule	Schedule giving optimum times usually for primary and/or secondary immunization.	Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007492	Iran	A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran.	Islamic Republic of Iran
D007676	Kidney Failure, Chronic	The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D004797	Enzyme-Linked Immunosorbent Assay	An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.	ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260	Female		Females
D006435	Renal Dialysis	Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.	Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006509	Hepatitis B	INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	Hepatitis B Virus Infection
D006510	Hepatitis B Antibodies	Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens.	Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti

Related Publications

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.

January 2020, PloS one,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection.

August 2000, Hepatology (Baltimore, Md.),

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Hepatitis B vaccine, hepatitis C virus infection, and haemodialysis.

September 1995, Lancet (London, England),

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Efficient haemodialysis improves the response to hepatitis B virus vaccination.

January 2002, Intervirology,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Hepatitis C virus infection in haemodialysis patients.

February 1991, Australian and New Zealand journal of medicine,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Hepatitis C virus infection in haemodialysis patients.

January 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

[Does efficient haemodialysis improve the response to hepatitis B virus vaccination?].

January 2004, Lijecnicki vjesnik,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Immune response after hepatitis A vaccination in haemodialysis patients: comparison with hepatitis B vaccination.

January 1994, Journal of gastroenterology and hepatology,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.

August 2008, Infection,

H Sorkhi, and M R H Roushan, and G H Al Hashemi, and M R E Dooki, and S Bai

Occult hepatitis C virus infection among haemodialysis patients.

September 2018, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology,